77 - Risk of Virologic Failure Among Treatment-experienced Suppressed People with HIV (PWH) Treated with Single-Tablet 2-Drug (2DR) vs 3-Drug (3DR) Regimens

On Demand

Participants should be aware of the following financial/non-financial relationships:

Paul Sax, MD: Gilead Sciences (Consultant, Grant/Research Support)Janssen (Consultant)Merck (Consultant, Research Grant or Support)ViiV (Consultant, Research Grant or Support)

Joseph J. Eron, MD: Gilead Sciences (Consultant, Research Grant or Support)Janssen (Consultant, Research Grant or Support)Merck (Consultant)ViiV (Consultant, Research Grant or Support)

Janna Radtchenko, MBA: Trio Health (Employee)

Helena Diaz-Cuervo, PhD: Gilead Sciences (Employee)

Mark Moore, PhD: Gilead Sciences (Employee)

Steven Santiago, MD: Gilead Sciences (Advisor or Review Panel member, Speaker's Bureau)Janssen (Speaker's Bureau)

Moti Ramgopal, MD FIDSA: Abbvie (Scientific Research Study Investigator, Speaker's Bureau)Gilead (Consultant, Scientific Research Study Investigator, Speaker's Bureau)Janssen (Consultant, Scientific Research Study Investigator, Research Grant or Support, Speaker's Bureau)Merck (Consultant, Scientific Research Study Investigator)ViiV (Consultant, Scientific Research Study Investigator, Speaker's Bureau)

Karam Mounzer, MD: Epividian (Advisor or Review Panel member)Gilead Sciences Inc. (Consultant, Scientific Research Study Investigator, Research Grant or Support, Speaker's Bureau)Janssen (Consultant, Research Grant or Support, Speaker's Bureau)Merck (Research Grant or Support, Speaker's Bureau)ViiV Healthcare (Consultant, Speaker's Bureau)

Richard Elion, MD: Gilead Sciences (Grant/Research Support, Advisor or Review Panel member, Speaker's Bureau)Janssen (Speaker's Bureau)Proteus (Grant/Research Support)Trio Health (Employee)ViiV (Advisor or Review Panel member)

Presenting Author(s)

Paul Sax, MD

Clinical Director
Brigham and Women's Hospital
Boston, MA, United States

Gilead Sciences (Consultant, Grant/Research Support)Janssen (Consultant)Merck (Consultant, Research Grant or Support)ViiV (Consultant, Research Grant or Support)

Slides Slides and Audio

Co-Author(s)

Joseph J. Eron, MD

Professor
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States

Gilead Sciences (Consultant, Research Grant or Support)Janssen (Consultant, Research Grant or Support)Merck (Consultant)ViiV (Consultant, Research Grant or Support)
JR

Janna Radtchenko, MBA

Senior Director, Analytics
Trio Health
Louisville, Colorado, United States

Trio Health (Employee)
HD

Helena Diaz-Cuervo, PhD

Gilead Sciences
Madrid, Madrid, Spain

Gilead Sciences (Employee)
MM

Mark Moore, PhD

Gilead Sciences
Uxbridge, England, United Kingdom

Gilead Sciences (Employee)
SS

Steven Santiago, MD

Chief Medical Officer
CareResource
Miami, Florida, United States

Gilead Sciences (Advisor or Review Panel member, Speaker's Bureau)Janssen (Speaker's Bureau)
MR

Moti Ramgopal, MD FIDSA

Chief Medical Officer
Midway Specialty Care Centers
Fort Pierce, Florida, United States

Gilead Sciences (Consultant, Research Grant or Support)Janssen (Consultant, Research Grant or Support)Merck (Consultant, Research Grant or Support)ViiV (Consultant, Research Grant or Support)
KM

Karam Mounzer, MD

Clinical Professor of Medicine
Philadelphia FIGHT
Philadelphia, PA, United States

Epividian (Advisor or Review Panel member)Gilead Sciences Inc. (Consultant, Scientific Research Study Investigator, Research Grant or Support, Speaker's Bureau)Janssen (Consultant, Research Grant or Support, Speaker's Bureau)Merck (Research Grant or Support, Speaker's Bureau)ViiV Healthcare (Consultant, Speaker's Bureau)
RE

Richard Elion, MD

Clinical Professor of Medicine
George Washington University School of Medicine
Washington, DC, United States

Gilead Sciences (Grant/Research Support, Advisor or Review Panel member, Speaker's Bureau)Janssen (Speaker's Bureau)Proteus (Grant/Research Support)Trio Health (Employee)ViiV (Advisor or Review Panel member)